Paniculidine B exhibits significant anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6 in cellular models. It has been studied for its potential use in managing chronic inflammatory conditions, including arthritis and inflammatory bowel disease. Research also suggests neuroprotective properties, where it reduces oxidative stress and microglial activation in neuronal cultures, indicating possible application in neurodegenerative disorders like Alzheimer’s disease. Additionally, preliminary studies show moderate antiproliferative effects against certain cancer cell lines, particularly in breast and colon cancers, by inducing apoptosis and cell cycle arrest. Its natural origin and biological profile make it a candidate for development as a lead compound in pharmaceuticals targeting inflammation and cancer.